Over and over again, investors who follow the med-tech space will see examples of companies generating solid revenue and profit growth in markets that are seen as slow-growth. In the case of Masimo (MASI), the company has used strong technology to add some spice to the pulse oximetry market. More recently, though, the company has struggled to generate the hoped-for growth from hemoglobin monitoring. Better execution here is the real key to the story - if Masimo can translate the potential of noninvasive hemoglobin monitoring into real sales, there could be upside to these shares.
Familiar Themes Closed Out 2012
Masimo's recent fourth quarter report was in some respects a microcosm of the company's story in recent...
Only subscribers can access this article, which is part of the PRO research library covering 3,608 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: